Non Invasive Diabetes Therapy Market - Global Industry Analysis, 2016-2024

The role of non-invasive therapy for diabetes market has been on a positive growth path in healthcare industry since 2014. Though the non-invasive therapy concept was brought way back in 1980, the market has not gained much attention leading to development of fewer such devices. DexCom's seven system and Medtronic's Guardian real-time glucose monitoring system are two such products developed and marketed worldwide. The influx of non-invasive therapy has reinforced the diabetes market in various ways ranging from economical cost incurred to patient treatment outcomes.

Many leading players along with new entrants are venturing in the market to capitalize and generate high ROI. As a result, noninvasive therapy market is expected to witness double digit growth rate over the forecast period.

Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-sample/54

The report covers market analysis across regions – North America, Europe, Asia Pacific, Latin America, Middle East and Africa.

Market Dynamics:

The World Health Organization projects diabetic population to reach 336 Mn by 2030 from 270 Mn in 2015. Increase in incidence rate of diabetic population will demand for non-invasive medication is expected to create favorable market opportunities for the players globally. Moreover, improving healthcare access along with focus on R&D could spur the overall non-invasive market size. Some companies are engaged in development of non-invasive system on photonic technology and occlusion spectroscopy technology.

The market will be further driven by changing macroeconomics and consumer preference. Healthcare expenditure has increased in developing regions. Large consumer base along with changing lifestyle is expected to create substantially new market opportunities for early entrants.

Regional Analysis:

Among regions, North America is expected to dominate the market throughout the forecast period. Moreover, North America is expected to grow at a fastest rate owing to high spending on R&D and presence of leading companies in the region. Prevalence rate of diabetes is high compared to other regions.

As per the initial study carried out by CA, North America and Europe are expected to account for over 65% of overall functional non-invasive diabetes therapy market. Healthcare providers are seeking this technology to manage the growing demand for diabetes. Growth in these regions is expected to be further driven by macroeconomic factors. The region as a whole spends over 5% of its GDP on research and GDP. Moreover, healthcare spending is highest in this region with North America accounting for 16.7% and Europe 10% of overall GDP in 2015.

Asia Pacific is expected to be driven by China and India. According to International Diabetes Federation, over 490 million people in China are suffering from diabetes. Country is pushing toward healthcare reforms. Many companies are emerging in the region. As a result,

To know more about this research, kindly visit: https://www.coherentmarketinsights.com/ongoing-insight/non-invasive-diabetes-therapy-market-54

Competition Landscape:

Some key players engaged in the market are Bio Tex, Calisto Medical, DexCom, Bayer, ACON Laboratories, B. Braun Melsungen, etc.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com

This release was published on openPR.